4.3 Review

Adipokines: Novel Players in Resistant Hypertension

Journal

JOURNAL OF CLINICAL HYPERTENSION
Volume 16, Issue 10, Pages 754-759

Publisher

WILEY-BLACKWELL
DOI: 10.1111/jch.12399

Keywords

-

Funding

  1. State of Sao Paulo Research Foundation (FAPESP)
  2. National Council for Scientific and Technological Development (CNPq)
  3. Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil

Ask authors/readers for more resources

Resistant hypertension (RH) is a multifactorial disease, frequently associated with obesity and characterized by blood pressure above goal (140/90 mm Hg) despite the concurrent use of >= 3 antihypertensive drugs of different classes. The mechanisms of obesity-related hypertension include, among others, aldosterone excess and inflammatory adipokines, which have demonstrated a significant role in the pathogenesis of metabolic syndrome and RH. This review aims to summarize recent studies on the role of the adipokines leptin, resistin, and adiponectin in the pathophysiology of RH and target-organ damage associated with this condition. The deregulation of adipokine levels has been associated with clinical characteristics frequently recognized in RH such as diabetes, hyperactivity of sympathetic and renin-angiotensin-aldosterone systems, and vascular and renal damage. Strategies to regulate adipokines may be promising for the management of RH and some clinical implications must be considered when managing controlled and uncontrolled patients with RH. (C) 2014 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available